5 Key Takeaways

• 1

  The FDA approved imlunestrant with abemaciclib for adults with ESR1-mutated advanced breast cancer after prior endocrine therapy.

• 2

  The Guardant360 CDx assay was authorized as a companion device to detect ESR1 mutations for patient selection.

• 3

  The EMBER-3 trial involved 874 adults with estrogen receptor-positive, HER2-negative breast cancer previously treated with aromatase inhibitors.

• 4

  Imlunestrant plus abemaciclib showed statistically significant improvement in progression-free survival compared to imlunestrant alone.

• 5

  In patients with ESR1 mutations, median progression-free survival was 11.1 months with the combination therapy versus 5.5 months with monotherapy.